677
document
Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure . PURPOSE To prospectively study the effect of oral brovincamine , a relatively selective cerebral vasodilator , on further deterioration of visual field in patients with normal-tension glaucoma ( NTG ) with low-normal intraocular pressure ( IOP ) . METHODS Fifty-two patients with NTG ( average age 57.7 years ) with an IOP that was consistently less than 15 mmHg were randomly assigned to receive oral brovincamine ( 20 mg three times daily ) or to an untreated control group . The groups were prospectively followed for 2 years with visual field examinations every 4 months , using the 30-2 Humphrey perimeter program . Changes in mean deviation ( MD ) , corrected pattern standard deviation ( CPSD ) , and total deviation ( TD ) at 74 test points were analyzed using regression analysis with linear mixed model . Data from one eye without media opacity of each subject were analyzed . RESULTS There were no differences between groups in age ; sex distribution ; refraction ; blood pressure ; baseline IOP ; MD , CPSD , or TD at each point . Changes in MD ( standard error [ SE ] ) during the study period were -0.778 ( 0.178 ) and -0.071 ( 0.195 ) dB/year in the control and brovincamine groups , respectively ; change in the control group was significantly more negative than in the brovincamine group . Change in CPSD ( SE ) was 0.032 ( 0.015 ) and 0.004 ( 0.016 ) dB/year in the control and brovincamine groups , respectively . Change in the control group was significantly positive , but the intergroup difference was not significant . Change in TD was significantly negative at six test points in the control group , whereas no points showed a significant trend in the brovincamine group ; the intergroup difference was significant . The average IOP was 13.2 mmHg and 13.1 mmHg in the control and brovincamine groups , respectively , and there was no significant intergroup difference . CONCLUSION Oral brovincamine may retard further visual field deterioration in patients with NTG who have low-normal IOP .
678
Intervention_Pharmacological
brovincamine
679
Intervention_Pharmacological
oral brovincamine
680
Intervention_Physical
cerebral vasodilator
681
Intervention_Pharmacological
oral brovincamine
682
Intervention_Control
untreated control group .
683
Intervention_Control
visual field examinations
684
Intervention_Pharmacological
brovincamine
685
Intervention_Pharmacological
brovincamine
686
Intervention_Pharmacological
brovincamine
687
Intervention_Pharmacological
brovincamine
688
Intervention_Pharmacological
brovincamine
689
Intervention_Pharmacological
Oral brovincamine
690
Outcome_Other
Effects
691
Outcome_Other
effect
692
Outcome_Other
Changes in mean deviation ( MD )
693
Outcome_Other
corrected pattern standard deviation ( CPSD )
694
Outcome_Other
total deviation ( TD )
695
Outcome_Physical
refraction
696
Outcome_Physical
blood pressure
697
Outcome_Physical
baseline IOP
698
Outcome_Other
MD
699
Outcome_Other
CPSD
700
Outcome_Other
TD
701
Outcome_Other
Changes in MD
702
Outcome_Other
Change in CPSD ( SE )
703
Outcome_Other
Change in TD
704
Outcome_Physical
average IOP
705
Participant_Condition
normal-tension glaucoma
706
Participant_Condition
low-normal intraocular pressure
707
Participant_Condition
normal-tension glaucoma ( NTG )
708
Participant_Condition
low-normal intraocular pressure
709
Participant_Sample-size
Fifty-two
710
Participant_Condition
NTG
711
Participant_Age
57.7
712
Participant_Condition
NTG